GB1492997A - Insulin derivatives - Google Patents
Insulin derivativesInfo
- Publication number
- GB1492997A GB1492997A GB3147575A GB3147575A GB1492997A GB 1492997 A GB1492997 A GB 1492997A GB 3147575 A GB3147575 A GB 3147575A GB 3147575 A GB3147575 A GB 3147575A GB 1492997 A GB1492997 A GB 1492997A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- lysine
- july
- amino acid
- insulin derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1492997 Insulin derivatives NATIONAL RESEARCH DEVELOPMENT CORP 21 July 1976 [28 July 1975] 31475/75 Addition to 1408757 Heading A5B [Also in Division C3] A pharmaceutical composition comprises an N - substituted insulin wherein the primary amino group of the B 29 (lysine) amino acid unit carries a carbamoyl group, N - substitution being absent from the primary group of the A 1 (glycine) and B 1 (phenylalanine) amino acid units, together with a physiologically - acceptable diluent or carrier. The composition is preferably in a form for parenteral administration and the preferred compound is B 29 (lysine) - N - carbamylinsulin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3147575A GB1492997A (en) | 1976-07-21 | 1976-07-21 | Insulin derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3147575A GB1492997A (en) | 1976-07-21 | 1976-07-21 | Insulin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1492997A true GB1492997A (en) | 1977-11-23 |
Family
ID=10323647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3147575A Expired GB1492997A (en) | 1976-07-21 | 1976-07-21 | Insulin derivatives |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1492997A (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631347A (en) * | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5700904A (en) * | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
EP2033662A1 (en) | 2004-01-21 | 2009-03-11 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
EP2107069A2 (en) | 2003-08-05 | 2009-10-07 | Novo Nordisk A/S | Novel insulin derivatives |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
EP2264066A2 (en) | 2003-08-05 | 2010-12-22 | Novo Nordisk A/S | Novel insulin derivatives |
EP2292653A1 (en) | 2005-02-02 | 2011-03-09 | Novo Nordisk A/S | Novel insulin derivatives |
US8710001B2 (en) | 2006-07-31 | 2014-04-29 | Novo Nordisk A/S | PEGylated, extended insulins |
US8710000B2 (en) | 2007-11-08 | 2014-04-29 | Novo Nordisk A/S | Insulin derivative |
US9018161B2 (en) | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
US9260502B2 (en) | 2008-03-14 | 2016-02-16 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
US9481721B2 (en) | 2012-04-11 | 2016-11-01 | Novo Nordisk A/S | Insulin formulations |
US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
US9688737B2 (en) | 2008-03-18 | 2017-06-27 | Novo Nordisk A/S | Protease stabilized acylated insulin analogues |
US9896496B2 (en) | 2013-10-07 | 2018-02-20 | Novo Nordisk A/S | Derivative of an insulin analogue |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
US10265385B2 (en) | 2016-12-16 | 2019-04-23 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
US10596229B2 (en) | 2010-10-27 | 2020-03-24 | Novo Nordisk A/S | Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action |
US11167035B2 (en) | 2005-12-28 | 2021-11-09 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
US12226458B2 (en) | 2019-05-20 | 2025-02-18 | Novo Nordisk A/S | System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus |
-
1976
- 1976-07-21 GB GB3147575A patent/GB1492997A/en not_active Expired
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
USRE37971E1 (en) | 1994-11-17 | 2003-01-28 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5922675A (en) * | 1994-11-17 | 1999-07-13 | Eli Lilly And Company | Acylated Insulin Analogs |
US6620780B2 (en) | 1995-03-17 | 2003-09-16 | Novo Nordisk A/S | Insulin derivatives |
US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
US7229964B2 (en) | 1995-03-17 | 2007-06-12 | Novo Nordisk A/S | Insulin derivatives |
US5700904A (en) * | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
US5631347A (en) * | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US8030269B2 (en) | 2001-06-04 | 2011-10-04 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
EP2287184A2 (en) | 2003-08-05 | 2011-02-23 | Novo Nordisk A/S | Novel insulin derivatives |
US8828923B2 (en) | 2003-08-05 | 2014-09-09 | Novo Nordisk A/S | Insulin derivatives |
EP2107069A2 (en) | 2003-08-05 | 2009-10-07 | Novo Nordisk A/S | Novel insulin derivatives |
US7615532B2 (en) | 2003-08-05 | 2009-11-10 | Novo Nordisk A/S | Insulin derivatives |
EP2264065A2 (en) | 2003-08-05 | 2010-12-22 | Novo Nordisk A/S | Novel Insulin Derivatives |
EP2264066A2 (en) | 2003-08-05 | 2010-12-22 | Novo Nordisk A/S | Novel insulin derivatives |
EP2275439A2 (en) | 2003-08-05 | 2011-01-19 | Novo Nordisk A/S | Novel insulin derivatives |
EP2368579A1 (en) | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
EP2033662A1 (en) | 2004-01-21 | 2009-03-11 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
EP2292653A1 (en) | 2005-02-02 | 2011-03-09 | Novo Nordisk A/S | Novel insulin derivatives |
USRE46170E1 (en) | 2005-02-02 | 2016-10-04 | Novo Nordisk A/S | Insulin derivatives |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
US8067362B2 (en) | 2005-02-02 | 2011-11-29 | Novo Nordisk As | Insulin derivatives |
US8476228B2 (en) | 2005-02-02 | 2013-07-02 | Novo Nordisk A/S | Insulin derivatives |
US8859493B2 (en) | 2005-02-02 | 2014-10-14 | Novo Nordisk A/S | Insulin derivatives |
EP2256130A1 (en) | 2005-02-02 | 2010-12-01 | Novo Nordisk A/S | Novel insulin derivatives |
US11167035B2 (en) | 2005-12-28 | 2021-11-09 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
US8710001B2 (en) | 2006-07-31 | 2014-04-29 | Novo Nordisk A/S | PEGylated, extended insulins |
US9018161B2 (en) | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
US8710000B2 (en) | 2007-11-08 | 2014-04-29 | Novo Nordisk A/S | Insulin derivative |
US9260502B2 (en) | 2008-03-14 | 2016-02-16 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
US9688737B2 (en) | 2008-03-18 | 2017-06-27 | Novo Nordisk A/S | Protease stabilized acylated insulin analogues |
US10259856B2 (en) | 2008-03-18 | 2019-04-16 | Novo Nordisk A/S | Protease stabilized acylated insulin analogues |
US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
US10596229B2 (en) | 2010-10-27 | 2020-03-24 | Novo Nordisk A/S | Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action |
US9481721B2 (en) | 2012-04-11 | 2016-11-01 | Novo Nordisk A/S | Insulin formulations |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
US9896496B2 (en) | 2013-10-07 | 2018-02-20 | Novo Nordisk A/S | Derivative of an insulin analogue |
US10596231B2 (en) | 2016-12-16 | 2020-03-24 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
US10265385B2 (en) | 2016-12-16 | 2019-04-23 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
US12226458B2 (en) | 2019-05-20 | 2025-02-18 | Novo Nordisk A/S | System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1492997A (en) | Insulin derivatives | |
IL89576A0 (en) | Peptide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same | |
IL79356A0 (en) | 1-substituted oxindole-3-carboxamides,their preparation and pharmaceutical compositions containing them | |
IL77430A (en) | 3-alkyl-and 3,8-dialkyl-6-thioxanthine and pharmaceutical compositions containing them | |
IE38979B1 (en) | Amides derived from quinoxaline | |
IE890175L (en) | Aminoacid glycerides. | |
GB1195200A (en) | Pharmaceutical Compositions. | |
GB1528713A (en) | N-(mercaptoacyl)-histidine | |
GB1505543A (en) | Benzodiazepine derivatives and a process for the preparation thereof | |
ES8703476A1 (en) | Composition containing a penem or carbapenem antibiotic. | |
GB1418595A (en) | N- 2-alkoxybenzoyl- amino acids and a process for producing the same | |
GB1243953A (en) | Benzdiazepine derivatives | |
SE7412147L (en) | ||
KR920014811A (en) | Tricyclic Pyridone Derivatives | |
IE37131L (en) | Insulin derivatives. | |
GB1505959A (en) | Pharmaceutical antihypertensive compositions | |
AU4807990A (en) | Antinephrotoxic perfusion solution | |
GB1391900A (en) | 3-benzylpyrido-3,4-e-astriazine and 1,2-dihydro-3-benzylpyrido- 3,4-e-as-triazine hydrochloride | |
ES2001665A6 (en) | N-alkylated tripeptides, process for their preparation, medicaments containing them and their use. | |
GB1463908A (en) | 1-dimethylamino-methyl-6-substituted-4h-s-triazolo-4,3-a- 1,4-benzodiazepine | |
AU5338596A (en) | Reductive alkylation process for the preparation of compound s containing at least two amino groups | |
GB1222294A (en) | Oxazinobenzodiazepine derivatives | |
GB1509445A (en) | Benzodiazepine derivatives and a process for the preparation thereof | |
GB1472937A (en) | Benzyl alcohol derivatives | |
GB1185616A (en) | 2-Sulfanilamido-3-Halogeno-Pyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |